Sign In
Buy ABT
$90.51
-0.0200 (-0.0221%)
At Close: Jun 24, 2026
7 Defensive Stocks Built to Withstand the Market's Worst Storms
06:00am, Tuesday, 30'th Apr 2024
While the equities sector experienced a bump higher for the week ending April 26, potential headwinds incentivize the case for defensive stocks to buy. First and foremost, the geopolitical headlines d
Abbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee
09:00am, Monday, 29'th Apr 2024
More than 20 million people in the U.S. are living with peripheral artery disease (PAD) yet there have been limited treatment options The first-of-its-kind Esprit™ BTK Everolimus Eluting Resorbable
2 Beaten-Down Dividend Stocks to Buy and Hold Forever
07:45am, Sunday, 28'th Apr 2024
Apple and Abbott Laboratories are facing multiple issues. However, both have excellent track records and important growth avenues.
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
10:05am, Monday, 22'nd Apr 2024
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Should You Pick Abbott Stock At $105 After An Upbeat Q1?
08:00am, Monday, 22'nd Apr 2024
Abbott (NYSE: ABT) recently reported its Q1 results, with revenues above and earnings exceeding our expectations. The company reported revenue of $10 billion and earnings of $0.98 on a per-share and a
20 Years To $300k? Building A $10,000 Dividend Portfolio From Scratch
07:00am, Saturday, 20'th Apr 2024
Focusing on consistent dividend growth can lead to higher returns in lower-risk areas. The portfolio emphasizes companies with wide-moat business models, strong financials, and a commitment to shareho
Abbott Labs Stock Falls as Q2 Guidance Outweighs Earnings Beat
02:25pm, Wednesday, 17'th Apr 2024
Shares of Abbott Laboratories (ABT) fell in intraday trading Wednesday, with second-quarter guidance seeming to outweigh first-quarter results that beat analyst estimates.
Abbott Laboratories (ABT) Q1 2024 Earnings Call Transcript
12:05pm, Wednesday, 17'th Apr 2024
Abbott Laboratories (NYSE:ABT ) Q1 2024 Results Conference Call April 17, 2024 9:00 AM ET Company Participants Mike Comilla - Vice President, Investor Relations Robert Ford - Chairman and Chief Execut
Q1 Earnings Review
12:05pm, Wednesday, 17'th Apr 2024
Pre-market futures are up slightly at this hour. Markets look to rebound off a three-day losing streak on the S&P 500 and Nasdaq; the blue-chip Dow outperformed the field yesterday, closing +0.17%.
Markets Try to Shake Off April Blues
11:36am, Wednesday, 17'th Apr 2024
Late March highs -- including all-time S&P levels -- have given way to profit-taking and existential concerns.
Abbott (ABT) Q1 Earnings Beat Estimates, Margins Contract
11:16am, Wednesday, 17'th Apr 2024
Abbott (ABT) delivers double-digit organic sales growth in its underlying base business in the first quarter of 2024.
Abbott (ABT) Reports Q1 Earnings: What Key Metrics Have to Say
10:31am, Wednesday, 17'th Apr 2024
Although the revenue and EPS for Abbott (ABT) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street es
Abbott (ABT) Tops Q1 Earnings and Revenue Estimates
09:41am, Wednesday, 17'th Apr 2024
Abbott (ABT) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $1.03 per share a year ago.
Abbott beats estimates, reports a 2.2% rise in Q1 sales
09:39am, Wednesday, 17'th Apr 2024
Abbott Laboratories on April 17 reported a 2.2% rise of $10 billion in its 2024 first-quarter sales which includes the impact of the anticipated decline in COVID-19 testing-related sales as compared t
Abbott Labs Stock Is Slipping. Disappointing Guidance Trumps a Strong Quarter.
08:41am, Wednesday, 17'th Apr 2024
Healthcare-products firm Abbott Laboratories' first-quarter earnings beat expectations, but second-quarter guidance was light.
